Items where Author is "Fadaie, M."

(2024) Evaluation of humoral and cellular immune responses against Vibrio cholerae using oral immunization by multi-epitope-phage-based vaccine. International Immunopharmacology. p. 10. ISSN 1567-5769

(2024) Exploring Advanced CRISPR Delivery Technologies for Therapeutic Genome Editing. Small Science. p. 33. ISSN 2688-4046

(2024) Highlighting roles of autophagy in human diseases: a perspective from single-cell RNA sequencing analyses. Drug Discovery Today. p. 20. ISSN 1359-6446

(2024) Immunoinformatic approach to the design of a novel multi-epitope vaccine against Leishmania major fused to human IgG-Fc. Research in Pharmaceutical Sciences. pp. 729-745. ISSN 1735-5362

(2024) Novel SARS-COV2 poly epitope phage-based candidate vaccine and its immunogenicity. Research in Pharmaceutical Sciences. pp. 573-590. ISSN 1735-5362

(2024) A Systems Biology Approach to the Pathogenesis of Celiac Disease: Identification of Potential Protective and Promoting Mechanisms. Advanced Biomedical Research. p. 14. ISSN 2277-9175

(2024) The enhancement of M13 phage titration by optimizing the origin of replication. Research in Pharmaceutical Sciences. pp. 338-346. ISSN 1735-5362

(2023) Nanoparticles as Powerful Tools for Crossing the Blood-brain Barrier. Cns & Neurological Disorders-Drug Targets. pp. 18-26. ISSN 1871-5273

(2023) Unraveling the potential of M13 phages in biomedicine: Advancing drug nanodelivery and gene therapy. Environmental Research. p. 20. ISSN 0013-9351

(2023) The mRNA Vaccines and Their Application to Combat Infectious Diseases and Cancers: A Review Article. Journal of Isfahan Medical School. pp. 658-673. ISSN 10277595 (ISSN)

(2022) Nanoparticles as Powerful Tools for Crossing the Blood-Brain Barrier. CNS Neurol Disord Drug Targets. ISSN 1871-5273

(2021) CD44 polymorphisms and its variants, as an inconsistent marker in cancer investigations. Mutation Research-Reviews in Mutation Research. ISSN 1383-5742

(2021) Implementation of docking, molecular dynamics and free energy to investigate drug potency of novel BCR-ABLT315I inhibitors as an alternative to ponatinib. Computational Toxicology. ISSN 24681113 (ISSN)